$NVS

Novartis broke ground on a $46K sq. ft. radioligand therapy facility in Texas, the fifth RLT site supporting its $23B US manufacturing investment ending in 2028.

Novartis broke ground on a Texas radioligand therapy facility, the fifth in its US network, part of a $23 billion manufacturing investment expected operational by 2028.

Complement inhibitors market projected for strong growth through 2036, driven by rising disease prevalence and C5/C3-targeted drug approvals across multiple indications.

IgA Nephropathy market projects 18.6% CAGR through 2036 from $1.5B base, driven by novel immunotherapies and recent FDA approvals reshaping kidney disease treatment.

DelveInsight's 2026 report shows robust rheumatoid arthritis pipeline with 75+ players developing 80+ drugs, featuring novel JAK and BTK inhibitors plus cell-based therapies.

Global antibiotic resistance market to grow from $9.78B (2026) to $12.72B (2031) at 5.4% CAGR, driven by rising drug-resistant infections and antimicrobial innovation.

Global radiopharmaceuticals market projected to grow from $8.28B (2026) to $15.21B (2035) amid rising cancer and cardiovascular disease incidence.

Global dermatomycoses market expected to grow significantly through 2035, driven by rising fungal infections and immunocompromised populations. Key players include Novartis, Bayer, and Sun Pharma.

Peptide drug conjugate market projected to reach $1.5 billion by 2031 with 14%+ CAGR, driven by targeted oncology therapies and innovative linker technologies from major biotech players.

PCPG cancer market projects 7.3% annual growth through 2036, valued at USD 300M in 2025, driven by novel drug classes and Novartis WELIREG leadership.

Novartis offers better dividend yields and diversification than Merck, with stronger long-term prospects despite both beating the S&P 500.

Generalized myasthenia gravis market valued at $5.9B in 2025, projected to grow 9.1% annually through 2036 as eight promising late-stage therapies advance.

IOB scientists unveil MitoCatch, engineered technology delivering healthy mitochondria to damaged cells. Early data shows improved cell survival in disease models.

CSPC market projected to surge from $5.14B (2025) to $11.75B (2036), driven by aging populations, new drug approvals, and emerging therapies.

SLE drug market projected to grow nearly 150% to $5.9B by 2034 on new therapies, but biosimilar competition and pricing pressure could limit upside.

Merck cut its Terns Pharmaceuticals offer to $53/share from $61 following disappointing TERN-701 trial data, with a competing bidder also withdrawing its offer.

President Trump's executive order imposes 100% tariffs on imported drugs, exempting 13 companies with MFN agreements and U.S. manufacturing commitments through 2029.

Over 120 pharmaceutical companies are developing 140+ drugs for systemic lupus erythematosus, with major players like Roche and Novartis advancing promising new treatment mechanisms.

Proleukin market projected to grow 6.1% annually to $1.68M by 2030, driven by rising cancer prevalence and expanded indications. Iovance Biotherapeutics strengthens position via 2023 acquisition.

American Heart Association launches Cardiovascular-Kidney-Metabolic initiative to address interconnected diseases affecting 90% of U.S. adults, emphasizing screening and prevention.